KYRNF.US KYORIN Pharmaceutical Co., Ltd.
- Market cap
- USD 592M
- P/E
- 25.8x
- P/B
- 0.67x
- ROE
- 2.3%
- Dividend yield
- 3.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is KYRNF.US undervalued?
Graham numberKYRNF.US trades 12.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KYORIN Pharmaceutical Co., Ltd. fundamental analysis
No fundamental analysis for KYORIN Pharmaceutical Co., Ltd. yet.
KYORIN Pharmaceutical Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KYORIN Pharmaceutical Co., Ltd.
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
Full company profileKYORIN Pharmaceutical Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KYORIN Pharmaceutical Co., Ltd. annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 103B | 106B | 113B | 120B | 130B | 126B | 119B |
| Gross Profit | 51.6B | 49.4B | 50.2B | 51.6B | 59.5B | 51.6B | 48.7B |
| Operating Income | 5.79B | 5.01B | 5.12B | 6.23B | 12.6B | 3.57B | 3.86B |
| EBITDA | - | - | 10.8B | 11.6B | 17.5B | 9.37B | 4.98B |
| Net Income | 6.13B | 3.93B | 4.72B | 5.48B | 9.09B | 3.45B | 3.30B |
| EPS | 107 | 69 | 82 | 95 | 158 | 60 | 57 |
| Balance Sheet | |||||||
| Total Assets | 167B | 172B | 176B | 178B | 194B | 195B | 189B |
| Total Liabilities | 42.5B | 47.4B | 50.6B | 46.9B | 57.3B | 53.0B | 48.3B |
| Shareholders' Equity | 125B | 125B | 125B | 131B | 136B | 142B | 140B |
| Cash & Short-term Investments | 27.4B | 27.0B | 19.4B | 13.9B | 15.0B | 11.8B | 13.7B |
| Cash Flow | |||||||
| Operating Cash Flow | 5.19B | 6.35B | 2.01B | 1.55B | 3.51B | 6.38B | - |
| Capital Expenditure | 5.12B | 2.69B | 9.41B | 6.25B | 6.29B | 3.98B | 0.00 |
| Free Cash Flow | 65.0M | 3.66B | -7.40B | -4.70B | -2.79B | 2.41B | - |
| Ratios | |||||||
| ROE | 4.9% | 3.2% | 3.8% | 4.2% | 6.7% | 2.4% | 2.3% |
| ROA | 3.7% | 2.3% | 2.7% | 3.1% | 4.7% | 1.8% | 1.7% |
| Net Profit Margin | 6.0% | 3.7% | 4.2% | 4.6% | 7.0% | 2.7% | 2.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
KYORIN Pharmaceutical Co., Ltd. dividends
- Dividend yield
- 3.49%
- Forward dividend
- 0.36 USD
- Payout ratio
- 95.8%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 3.30B | 57 | 95.8% |
| 2025 | JPY 3.02B | 52 | 33.2% |
| 2024 | JPY 3.01B | 52 | 55.0% |
| 2023 | JPY 3.02B | 53 | 63.8% |
| 2022 | JPY 3.77B | 66 | 95.8% |
| 2021 | JPY 4.35B | 76 | 70.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns KYORIN Pharmaceutical Co., Ltd.
- Insiders 35.81%
- Institutions 23.42%
- Public & others 40.77%
- Shares outstanding 57.4M
- Free float 41.9M
KYORIN Pharmaceutical Co., Ltd. company profile
- Company name
- KYORIN Pharmaceutical Co., Ltd.
- Ticker
- KYRNF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1,982
- Fiscal year end
- March
- Address
- A, Tokyo, Japan, 100-0004
- Phone
- 81 3 6374 9700
- Website
- kyorin-pharm.co.jp
About KYORIN Pharmaceutical Co., Ltd.
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
KYORIN Pharmaceutical Co., Ltd. management
7- Mr. Yutaka OgiharaPresident, CEO & Chairman · born 1967
- Mr. Yasuji KuroseCFO, CSO, Managing Executive Officer, Director of Corporate Planning & Executive Director · born 1970
- Junichi IshiyamaManaging Executive Officer, CSO & Head of Drug Discovery Div.
- Mr. Kenichi NakamuraManaging Exec. Officer, CMO & President of KYORIN Pharma Grp Fac Co., Ltd.
- Kiyoo UeharaManaging Executive Officer, CHRO & General Affairs Manager
- Takaaki KajiSr Managing Executive Officer, CBDO & Head of Business Development Headquarters
- Mr. Noriaki TamuraManaging Executive Officer, CCO, Head of Pharmaceutical Sales Division & Director · born 1966